Symptomatic and quality of life response to tolterodine in subgroups of men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia

World Journal of Urology

Volumn 28, Issue 3, 2010, Pages 353-357

  Hofner K ^a   Burkart, M ^b   Jacob, G ^b   Jonas, U ^c  

^a Evangelisches Krankenhaus Oberhausen   (Germany)

^b PFIZER INC   (United States)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

LUTS; OAB; Tolterodine ER

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BENZHYDRYL DERIVATIVE; CRESOL; MUSCARINIC RECEPTOR BLOCKING AGENT; PHENYLPROPANOLAMINE; TOLTERODINE;

AGE; AGED; ARTICLE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; NONPARAMETRIC TEST; OVERACTIVE BLADDER; PATIENT SATISFACTION; PROBABILITY; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; PROSTATISM; QUALITY OF LIFE; REGRESSION ANALYSIS; TREATMENT OUTCOME; URODYNAMICS;

ADRENERGIC ALPHA-ANTAGONISTS; AGE FACTORS; AGED; BENZHYDRYL COMPOUNDS; CRESOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PATIENT SATISFACTION; PHENYLPROPANOLAMINE; PROBABILITY; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; PROSTATISM; QUALITY OF LIFE; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URODYNAMICS;

EID: 77952876027     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-009-0460-7     Document Type: Article

References (17)

1. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87: 760-766.
2. Abrams P, Cardozo L, Khoury S, Wein A (2005) Incontinence, vol 2. Management Health Publication Ltd, Plymouth.
3. Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB (2004) Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 94: 817-820.
4. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G (2003) Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 169: 2253-2256.
5. Kaplan SA (2004) Use of muscarinic receptor antagonists as monotherapy in men with lower urinary tract symptoms who failed previous therapy with alpha blockers. J Urol 171(Suppl): 917 (abstract).
6. Lim E, Chia SJ (2005) Combination therapy using alpha-blocker and antimuscarinic drugs in men with lower urinary tract symptoms suggestive of bladder outlet obstruction and an overactive bladder: is it safe and efficacious? Neurourol Urodyn 24(5-6): 205 (abstract).
7. Berges R, Dreikorn K, Höfner K, Jonas U, Laval KU, Madersbacher S, Michel MC, Muschter R, Oelke M, Pientka L, Tschuschke C, Tunn U (2003) Leitlinien der Deutschen Urologen zur Diagnostik des benignen Prostatasyndroms (BPS). Urologe A 42: 584-590.
8. Roehrborn CG (2006) Drug treatment for LUTS and BPH: new is not always better. Eur Urol 49: 5-7.
9. Kaplan SA, Walmsley K, Te AE (2005) Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 174: 2273-2275 (discussion 2275-2276).
10. Saito H, Yamada T, Oshima H et al (1999) A comparative study of the efficacy and safety of tamsulosin hydrochloride alone and combination of propiverine hydrochloride and tamsulosin in the benign prostatic hypertrophy with pollakiuria and/or urinary incontinence. Jpn J Urol Surg 12: 525-536.
11. Abrams P, Kaplan S, De Koning Gans HJ, Millard R (2006) Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 175: 999-1004 (discussion 1004).
12. Coyne KS, Matza LS, Thompson CL (2005) The responsiveness of the overactive bladder questionnaire (OAB-q). Qual Life Res 14: 849-855.
13. Roehrborn CG, McConnell JD, Barry MJ, Benaim E, Bruskewitz RC, Blute ML, Holtgrewe HL (2006) AUA guideline on the Management of Benign Prostatic Hyperplasia. http://www. auanet. org/guidelines/bph. cfm, Accessed June 19, 2006.
14. Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ (2004) EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 46: 547-554.
15. Michel MC, de la Rosette JJ, Piro M, Goepel M (2004) Does concomitant stress incontinence alter the efficacy of tolterodine in patients with overactive bladder? J Urol 172: 601-604.
16. Michel MC, Schneider T, Krege S, Goepel M (2002) Does gender or age affect the efficacy and safety of tolterodine? J Urol 168: 1027-1031.
17. Michel MC, de la Rosette JJ, Piro M, Schneider T (2005) Comparison of symptom severity and treatment response in patients with incontinent and continent overactive bladder. Eur Urol 48: 110-115.